Show simple item record

dc.contributor.advisorSenatore, C.
dc.contributor.advisorCharlier, B.
dc.contributor.advisorTruono, A.
dc.contributor.advisorPunzi, R.
dc.contributor.advisorD’Aniello, F.
dc.contributor.advisorBoffa, N.
dc.contributor.advisorIzzo, Viviana
dc.contributor.advisorConti, Valeria
dc.contributor.advisorRussomanno, Giusy
dc.contributor.advisorManzo, V.
dc.contributor.advisorFilippelli, Amelia
dc.contributor.advisorMazzeo M, M.
dc.date.accessioned2015-01-29T14:09:18Z
dc.date.available2015-01-29T14:09:18Z
dc.date.issued2015
dc.identifier.citationSenatore C, Charlier B, Truono A, Punzi R, D’Aniello F, Boffa N, Izzo V, Conti V, Russomanno G, Manzo V, Filippelli A, Mazzeo M. A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno. Translational Medicine @ UniSa 2015, 11(10):55-58en_US
dc.identifier.issn2239-9747en_US
dc.identifier.urihttp://hdl.handle.net/10556/1652
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-456
dc.description.abstractAbacavir is a nucleoside reverse transcriptase inhibitor largely used as part of the antiretroviral therapy in Human Immunodeficiency Virus (HIV)-infected patients. Some individuals (2-9%) who start an abacavir treatment show an immunologic reaction indicated as hypersensitivity reaction syndrome (HSR) that is often responsible for therapy discontinuation and could represent a life-threatening event. Some studies demonstrated a correlation between this adverse reaction and the class I of the major histocompatibility complex (MHC) allele, HLA-B*57.01, in several populations, including Caucasians. Nowadays, International HIV treatment guidelines recommend the HLA-B*57.01 genotyping before abacavir administration to reduce the incidence of HSR. Both male and female HIV-infected patients were enrolled at the Infectious Diseases Division at the University Hospital of Salerno, and admitted to a prospective HLA-B*57.01 screening. Genetic analysis was carried out through two sequential Real-Time PCR reactions in which Sybr-Green was used. Out of 248 patients, 215 were Italians from Southern Italy and 33 were coming from several non-EU members countries. All were genotyped: 6 Italians (2.8%) and 1 of the non-EU group (3%) were identified as HLA-B*57.01 carriers. In this paper we present our experience in the field of abacavir pharmacogenetic and confirm the importance of Real Time PCR as a valid and cost-effective HLA-B*57.01 typing methodology.en_US
dc.format.extentP. 55-58en_US
dc.language.isoenen_US
dc.sourceUniSa. Sistema Bibliotecario di Ateneoen_US
dc.subjectAbacaviren_US
dc.subjectHIVen_US
dc.subjectHLA-B*57.01en_US
dc.subjectHypersensitivity reactionen_US
dc.subjectReal-Time PCRen_US
dc.titleA Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salernoen_US
dc.typeArticleen_US
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record